BioScrip, Inc. (NASDAQ:BIOS)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Group LLC in a research report issued on Thursday. They presently have a $4.00 price target on the stock, up from their prior price target of $3.00. Jefferies Group LLC’s price target points to a potential upside of 38.41% from the stock’s previous close.
A number of other research firms have also commented on BIOS. Barrington Research upped their price objective on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a research note on Monday, June 26th. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Wednesday, June 28th. Finally, ValuEngine lowered shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $3.75.
Shares of BioScrip (BIOS) opened at 2.89 on Thursday. BioScrip has a 12-month low of $0.98 and a 12-month high of $3.43. The firm has a 50-day moving average of $2.81 and a 200 day moving average of $2.01. The firm’s market capitalization is $349.64 million.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The firm had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The business’s revenue was down 6.2% on a year-over-year basis. On average, equities research analysts expect that BioScrip will post ($0.38) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2797326/bioscrip-inc-nasdaqbios-stock-rating-reaffirmed-by-jefferies-group-llc.html.
Large investors have recently bought and sold shares of the stock. Gilder Gagnon Howe & Co. LLC raised its stake in BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock worth $41,298,000 after buying an additional 10,845,410 shares in the last quarter. FMR LLC raised its stake in BioScrip by 36.1% in the first quarter. FMR LLC now owns 4,803,000 shares of the company’s stock worth $8,165,000 after buying an additional 1,273,205 shares in the last quarter. Wynnefield Capital Inc. raised its stake in BioScrip by 2.7% in the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock worth $6,460,000 after buying an additional 100,000 shares in the last quarter. State Street Corp raised its stake in BioScrip by 10.6% in the fourth quarter. State Street Corp now owns 1,456,697 shares of the company’s stock worth $1,515,000 after buying an additional 139,110 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in BioScrip by 15.3% in the first quarter. Geode Capital Management LLC now owns 944,054 shares of the company’s stock worth $1,604,000 after buying an additional 125,098 shares in the last quarter. 91.16% of the stock is currently owned by institutional investors.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.